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Introduction 
Alzheimer’s Disease (AD) is a form of dementia, defined by histopathological 
features like senile plaques and neurofibrillary tangles, with clinical symptoms such as loss 
of memory & executive functions, which may only be apparent many years later1). As there 
is no known treatment for AD once dementia set in, and with the increasing cost of care for 
AD, there is a growing interest in diagnosing subjects for possible AD conversion before 
clinical symptoms appear. Amyloid imaging using Positron Emission Tomography (PET) 
provides a non-invasive, in-vivo diagnosis of subjects based on cerebral amyloid load. In 
developing successful amyloid radiotracers to diagnose the amyloid burden in subjects, many 
challenges to consider (e.g. poor in-vitro to in-vivo conversion, different Aβ and tau binding 
etc.). To facilitate decision making in moving candidate amyloid radiotracers to clinical 
application, a screening methodology of amyloid PET radiotracers based on in-silico data 
and a biomathematical model was developed by the authors. 
The biomathematical model developed was based on a 1-tissue compartment model 
developed by Guo et al. for CNS tracers2). Two in-vitro pharmacological parameters, free 
fraction in plasma (fP) and free fraction in tissue (fND) are required to generate kinetic 
parameters for SUVR simulations. However, fP values of only three amyloid radiotracers were 
reported in literatures and were measured using either rat or monkey plasma (Table 1). We 
proposed a methodology based on in-silico lipophilicity values and a relational model3) to 
derive in-silico fP and fND values. The purpose of this project was to validate the in-silico fP 
values with in-vitro fP values measured by means of ultrafiltration for 3 available amyloid 
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radiotracers in CYRIC, Tohoku University – [11C]BF227, [11C]PIB and [18F]florbetapir. 
 
Methods 
Ultrafiltration 
One tube of frozen human plasma samples (4 mL, with Heparin) was defrost at 37°C 
for 30 min in a pre-warmed incubator. Presence of triglycerides and plasma pH were 
checked4). 4 mL of PBS were pipetted into another storage tube and kept in the incubator for 
30 min. For each tracer, 1% (F-18) or 5% (C-11) of the total volume of plasma sample (40 
μL and 200 μL respectively), of radioactive compounds were pipetted into plasma and PBS 
storage tubes respectively. Both tubes were vortexed and incubated for 30 min at 37°C, with 
side-to-side tiling motion to ensure continuous mixing. 
Radioactive plasma and PBS were pipetted into 3 Centrifree tubes (1 mL, 10 kDa 
MWCO, Millipore) each and centrifuged with sliding buckets at 2000 x g for 20 min at 37°C, 
using a temperature-controlled centrifugal machine (Kubota 2800, Japan)5). The Centrifree 
tubes of both plasma and PBS each, were weighted as a whole with their respective 
ultrafiltrate containers, before and after centrifugation to obtain the weight of the top plasma 
(Wpti) and bottom ultrafiltrate (Wpfi).  
Fifteen empty gamma counter tubes were weighed. 100 μL of the plasma in the 
original storage tubes (Cpi), plasma in the top part of the Centrifree tubes (Cpti) and the 
respective ultrafiltrate (Cpfi) were pipetted into gamma counter tubes and radioactivity in each 
tube was measured using WIZARD2 (2480, Perkin Elmer) in three aliquots. The same 
procedures were repeated for PBS to obtain Cbi, and Cbfi only. For each tracer, fP was 
measured using three aliquots to determine variability within each measurement and 
measurements were carried thrice to determine reproducibility of measurements. 
 
Calculation of recovery, non-specific binding (NSB) & free fraction in plasma (fP) 
Due to NSB in ultrafiltration, a few methods were proposed to calculate fP from 
ultrafiltration measurements, with basic method used as a standard4. However, it does not 
correct for NSB and hence a “reference” method was introduced to correct for NSB6). 
However, correcting fP measurements using PBS was said to be inappropriate as PBS has 
different viscosity properties from plasma7). Moreover, ultrafiltration measurements were 
dependent on volume ratio of ultrafiltrate, hence a mass-balanced method7) was introduced 
to correct for possible differences in measurements due to differences in volume ratio. The 
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various methods of determining fP values were explored to compare with reported fP values 
(Table 1). 
 
A. Based on Mass-Balanced Method7): 
Protein binding, recovery were calculated by mass balance as follows: 
%Recovery =  ���𝐶𝐶pf𝑖𝑖 × 𝑊𝑊pf𝑖𝑖� + �𝐶𝐶pt𝑖𝑖 × 𝑊𝑊pt𝑖𝑖�(𝐶𝐶p𝑖𝑖 × 𝑊𝑊p𝑖𝑖) �𝑛𝑛𝑖𝑖  ×  100%𝑛𝑛  (1) %NBS =  ��1 − 𝐶𝐶bf𝑖𝑖
𝐶𝐶b𝑖𝑖
�
𝑛𝑛
𝑖𝑖
 ×  𝟏𝟏𝟏𝟏𝟏𝟏%
𝑛𝑛
 (2) 
𝑓𝑓P =  �� 𝐶𝐶pf𝑖𝑖  ×  𝑉𝑉pf𝑖𝑖
�𝐶𝐶pt𝑖𝑖  ×  𝑉𝑉pt𝑖𝑖� + �𝐶𝐶pf𝑖𝑖  ×  𝑉𝑉pf𝑖𝑖��𝑛𝑛𝑖𝑖 × 100%𝑛𝑛  (3) 
B. Based on Reference Method6): 
𝑓𝑓P =  ��𝐶𝐶pf𝑖𝑖 𝐶𝐶p𝑖𝑖⁄𝐶𝐶bf𝑖𝑖 𝐶𝐶b𝑖𝑖⁄ �  ×  100%𝑛𝑛𝑛𝑛𝑖𝑖  (4) 
C. Based on Basic Method4): 
𝑓𝑓P =  𝐶𝐶pf𝑖𝑖𝐶𝐶p𝑖𝑖  × 100% (5) 
where i refers to the no. of samples measured (n = 1 ~ 3), p refers to plasma and b refers to 
PBS (buffer), t refers to top part of Centrifree tube, f refers to the ultrafiltrate part of the 
Centrifree tube, without t or f means the total of both top and filtrate part of Centrifree tube. 
C refers to the radioactive concentration measured using WIZARD and W refers to the weight 
of the sample. For example, Cpi is radioactive concentration in plasma, Wpi is the weight of 
total weight of the samples in the top of the Centrifree tube and in the ultrafiltrate container, 
Cti and Wti are the radioactive concentration and weight of sample in the top of the Centrifree 
tube, Cfi and Wfi are the radioactive concentration and weight of the ultrafiltrate in the filtrate 
container. 
 
Results  
Table 2 shows the calculated recovery, NSB and fP calculated by the 3 methods 
mentioned. The in-silico fP values are also shown in Table 2. 
 
Discussions 
Up to date, very few literatures have reported the values of plasma free fraction (fp), 
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(Table 1), and the equations used to calculate fP were not discussed. fP values were measured 
by means of thin layer chromatography and ultrafiltration and no fND values were reported in 
the literatures. fP values measured using animals’ (rat and monkey) plasma samples were used 
for measurements (Table 1), instead of human plasma samples, which made comparison of 
reported and measured fP values (Table 2) difficult. 
Equilibrium Dialysis is the gold standard used to measure both fP and fND , but was 
not carried out due to limitations and long time required for measurement. Ultrafiltration was 
applied instead but measurements could only be used reliably if verified with ultrafilitration. 
However, non-specific binding (NSB) should be kept low (<5%)4), and volume of ultrafiltrate 
should be kept controlled within 40% of total volume4,5). The average volume ratio of the 
ultrafiltrate is kept less than 20%, with an overall mean of 18.4% and standard deviation of 
0.5%. The variabilities within experiment and between the experiments, were less than 5% 
regardless of the tracers used and the calculation methods applied (Table 2). Hence, the 
procedure parameters were well-controlled for fP measurements. 
[11C]PIB had the highest NSB to filter membrane, followed by [11C]BF227 then 
[18F]florbetapir, with the same order for fP values calculated using mass-balanced and basic 
methods. [11C]BF227 has the highest referenced fP values, followed by [11C]PIB then 
[18F]florbetapir. In-silico fP values showed similar trend with reference fP values.  
Due to the binding nature of all three amyloid tracers measured, NSB values measured 
were always greater than 50% and %Recovery values measured were also less than 90%, 
hence ultrafiltration was not a suitable method for measuring fP. Moreover, only three clinical 
amyloid radiotracers were available for fP measurements hence it was difficult to use the fP 
values for validating in-silico fP values or for correlating with clinical outputs or for use in 
in-silico/in-vitro model prediction. 
 
Conclusions 
The results showed that ultrafiltration was not a suitable method for measuring fP 
values. Although only three radiotracers were evaluated, the measured results showed a 
similar trend in terms of clinical tracer evaluation, whereby [11C]PIB showed better amyloid 
binding then [11C]BF227 and [18F]florbetapir. If more clinical radiotracers were available, 
further evaluation on the possible co-relationships could be carried out. 
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Table 1.  Free fraction in plasma (fP) reported in Literatures. 
Tracer fP (%) Method of Measurement Species References 
[11C]PIB 14 Thin-layer Chromatography at 60 min Rat (8) 
[18F]Flutemetamol 1 (0.9–1.3)# Ultrafiltration Rat (8) 
[11C]MeS-IMPY 0.83±0.17* Ultrafiltration Monkey (9) 
  
#Range of fP values 
  *Mean ± Standard deviation 
 
 
Table 2.  Recovery, NSB, Plasma Free Fraction (fP) and ultrafiltrate volume ratio measured using ultrafiltration 
(Mean ± Standard deviation) and in-silico fp values (Right) for [11C]PIB, [18F]Florbetapir and [11C]BF227. 
Tracers Recovery  (%) 
NSB 
(%) 
Volume 
ratio (%) 
Mass balanced 
fP (%) 
Referenced 
fP (%) 
Basic fP  
(%) 
In-Silico 
fP (%) 
[11C]PIB 82.1±1.3 99.0±0.2 18.7±0.4 0.04±0.02 15.0±4.4 0.13±0.11 30.3 
[18F]Florbetapir 83.3±0.5 65.6±2.3 16.7±0.8 0.64±0.07 9.28±0.62 3.17±0.19 27.0 
[11C]BF227 81.7±1.5 94.7±0.3 18.1±0.5 0.19±0.01 16.2±0.7 0.84±0.03 30.4 
 
 
